Immune Checkpoint Blockade in Lung Cancer

被引：0
|
作者：
Somasundaram, Aswin [1 ]
Socinski, Mark A. [1 ]
Villaruz, Liza C. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Pittsburgh, PA 15232 USA
来源：
DISCOVERY MEDICINE | 2016年 / 22卷 / 119期
关键词：
UP-REGULATION; DOUBLE-BLIND; MULTICENTER; EXPRESSION; NIVOLUMAB; SAFETY; LYMPHOCYTES; DOCETAXEL; ANTIBODY; PHASE-2;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the therapeutic landscape of advanced lung cancer. The adaptive immune system has developed a sophisticated method of tumor growth control, but T-cell activation is regulated by various checkpoints. Blockade of the immune checkpoints with therapies targeting the PD-1 pathway, such as nivolumab and pembrolizumab, has been validated as a therapeutic approach in non-small cell lung cancer. Newer therapies and novel combinations are also being evaluated, and the use of biomarkers in conjunction with these drugs is an area of active investigation. This review summarizes the current evidence for the efficacy and safety of the above approaches in the treatment of lung cancer.
引用
收藏
页码：56 / 66
页数：11
相关论文
共 50 条
  • [41] Optimizing targeted therapy and immune checkpoint blockade therapy in Kras mutant lung cancer
    Choi, Hyejin
    Deng, Jiehui
    Silk, Tarik
    Powers, Ann
    Boiarsky, Jonathan
    Merghoub, Taha
    Wong, Kwok-Kin
    Wolchok, Jedd
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [42] Understanding the checkpoint blockade in lung cancer immunotherapy
    Dal Bello, Maria Giovanna
    Alama, Angela
    Coco, Simona
    Vanni, Irene
    Grossi, Francesco
    DRUG DISCOVERY TODAY, 2017, 22 (08) : 1266 - 1273
  • [43] Immune Checkpoint Blockade
    Naidoo, Jarushka
    Page, David B.
    Wolchok, Jedd D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (03) : 585 - +
  • [44] PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
    Kadam, Pournima
    Sharma, Sherven
    VACCINES, 2020, 8 (02) : 1 - 13
  • [45] Immune checkpoint inhibitors in lung cancer
    Koleczko, S.
    Wolf, J.
    INTERNIST, 2020, 61 (07): : 676 - 681
  • [46] Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade
    Moller, Miriam
    Turzer, Steffi
    Ganchev, Georgi
    Wienke, Andreas
    Schutte, Wolfgang
    Seliger, Barbara
    Riemann, Dagmar
    CANCERS, 2022, 14 (15)
  • [47] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Anagnostou, Valsamo
    Forde, Patrick M.
    White, James R.
    Niknafs, Noushin
    Hruban, Carolyn
    Naidoo, Jarushka
    Marrone, Kristen
    Sivakumar, I. K. Ashok
    Bruhm, Daniel C.
    Rosner, Samuel
    Phallen, Jillian
    Leal, Alessandro
    Adleff, Vilmos
    Smith, Kellie N.
    Cottrell, Tricia R.
    Rhymee, Lamia
    Palsgrove, Doreen N.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine
    Georgiades, Christos
    Verde, Franco
    Illei, Peter
    Li, Qing Kay
    Gabrielson, Edward
    Brock, Malcolm V.
    Isbell, James M.
    Sauter, Jennifer L.
    Taube, Janis
    Scharpf, Robert B.
    Karchin, Rachel
    Pardoll, Drew M.
    Chaft, Jamie E.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Velculescu, Victor E.
    CANCER RESEARCH, 2019, 79 (06) : 1214 - 1225
  • [48] Photothermal therapies to improve immune checkpoint blockade for cancer
    Balakrishnan, Preethi B.
    Sweeney, Elizabeth E.
    Ramanujam, Anvitha S.
    Fernandes, Rohan
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2020, 37 (03) : 34 - 49
  • [49] Perspective: cancer vaccines in the era of immune checkpoint blockade
    Jonathan Cebon
    Mammalian Genome, 2018, 29 : 703 - 713
  • [50] Immune-checkpoint blockade — durable cancer control
    Elizabeth I. Buchbinder
    F. Stephen Hodi
    Nature Reviews Clinical Oncology, 2016, 13 : 77 - 78
12345